Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy
Melanoma patients harbouring BRAFV600E mutation generally develop resistance to targeted therapy. In this study, the authors demonstrate that SREBP-1-mediated induction of lipid biosynthesis contributes to therapy resistance in BRAF mutant melanoma.
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c1bb7bfd70be4f42827f1d7f1e16991f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c1bb7bfd70be4f42827f1d7f1e16991f |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:c1bb7bfd70be4f42827f1d7f1e16991f2021-12-02T15:34:39ZSustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy10.1038/s41467-018-04664-02041-1723https://doaj.org/article/c1bb7bfd70be4f42827f1d7f1e16991f2018-06-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-04664-0https://doaj.org/toc/2041-1723Melanoma patients harbouring BRAFV600E mutation generally develop resistance to targeted therapy. In this study, the authors demonstrate that SREBP-1-mediated induction of lipid biosynthesis contributes to therapy resistance in BRAF mutant melanoma.Ali TalebiJonas DehairsFlorian RambowAljosja RogiersDavid NittnerRita DeruaFrank VanderhoydoncJoao A. G. DuarteFrancesca BosisioKathleen Van den EyndeKris NysMónica Vara PérezPatrizia AgostinisEtienne WaelkensJoost Van den OordSarah-Maria FendtJean-Christophe MarineJohannes V. SwinnenNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-11 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Ali Talebi Jonas Dehairs Florian Rambow Aljosja Rogiers David Nittner Rita Derua Frank Vanderhoydonc Joao A. G. Duarte Francesca Bosisio Kathleen Van den Eynde Kris Nys Mónica Vara Pérez Patrizia Agostinis Etienne Waelkens Joost Van den Oord Sarah-Maria Fendt Jean-Christophe Marine Johannes V. Swinnen Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy |
| description |
Melanoma patients harbouring BRAFV600E mutation generally develop resistance to targeted therapy. In this study, the authors demonstrate that SREBP-1-mediated induction of lipid biosynthesis contributes to therapy resistance in BRAF mutant melanoma. |
| format |
article |
| author |
Ali Talebi Jonas Dehairs Florian Rambow Aljosja Rogiers David Nittner Rita Derua Frank Vanderhoydonc Joao A. G. Duarte Francesca Bosisio Kathleen Van den Eynde Kris Nys Mónica Vara Pérez Patrizia Agostinis Etienne Waelkens Joost Van den Oord Sarah-Maria Fendt Jean-Christophe Marine Johannes V. Swinnen |
| author_facet |
Ali Talebi Jonas Dehairs Florian Rambow Aljosja Rogiers David Nittner Rita Derua Frank Vanderhoydonc Joao A. G. Duarte Francesca Bosisio Kathleen Van den Eynde Kris Nys Mónica Vara Pérez Patrizia Agostinis Etienne Waelkens Joost Van den Oord Sarah-Maria Fendt Jean-Christophe Marine Johannes V. Swinnen |
| author_sort |
Ali Talebi |
| title |
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy |
| title_short |
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy |
| title_full |
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy |
| title_fullStr |
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy |
| title_full_unstemmed |
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy |
| title_sort |
sustained srebp-1-dependent lipogenesis as a key mediator of resistance to braf-targeted therapy |
| publisher |
Nature Portfolio |
| publishDate |
2018 |
| url |
https://doaj.org/article/c1bb7bfd70be4f42827f1d7f1e16991f |
| work_keys_str_mv |
AT alitalebi sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT jonasdehairs sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT florianrambow sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT aljosjarogiers sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT davidnittner sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT ritaderua sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT frankvanderhoydonc sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT joaoagduarte sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT francescabosisio sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT kathleenvandeneynde sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT krisnys sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT monicavaraperez sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT patriziaagostinis sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT etiennewaelkens sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT joostvandenoord sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT sarahmariafendt sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT jeanchristophemarine sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy AT johannesvswinnen sustainedsrebp1dependentlipogenesisasakeymediatorofresistancetobraftargetedtherapy |
| _version_ |
1718386804934049792 |